**Table 2.** Intervention drugs assessed in the paediatric febrile urinary tract infection clinical trials

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Drug Category** | **Drug name** | | **Route** | **Dosage in mg/kg/d** | **Dosage in IU/d** | **Duration in days (range)** | **Cure rate**† **% (CI)** | **Number of arms assessed** | **Number of studies (%)** | **Reference** |
| Penicillins | | Amoxicillin or ampicillin | po | 50-100 | - | 4-18 | na |  | 3 (10.0) | 36,40,43 |
| Co-amoxiclav | po | 50-150\*\* | - | 4-18 | 98.327 (94.6 – 100.0) | 5 | 4 (13.3) | 36,38,44,45 |
| Temocillin | IV | na | - | 3-7 | 94.3 (88.1 - 98.5) | 2 | 1 (3.3) | 36 |
| 1st generation cephalosporins | | Cefadroxil | po | 30 | - | 7-10 | Na |  | 1 (3.3) | 41 |
| Cefalothin | po | 100 | - | 3-10 | Na |  | 2 (6.6) | 34,43 |
| Cefalexin | po | na | - | 10-14 | Na |  | 1 (3.3) | 30 |
| 2nd generation cephalosporins | | Cefuroxime axetil | po | 30 | - | 7-10 | Na |  | 1 (3.3) | 41 |
| 3rd generation cephalosporins | | Ceftibuten | po | 9 | - | 9-14 | Na |  | 3 (10.0) | 37,39,48 |
| Cefetamet pivoxil | po | 20-40 | - | 7-10 | Na |  | 1 (3.3) | 45 |
| Cefixime | po | 8-16 | - | 6-14 | 96.1 (93.6 - 98.0) | 11 | 9 (30.0) | 23-27,31-33,40,49-51 |
| Ceftriaxone | IV | 50-75 | - | 1-14 | 95.8 (92.8- 98.1) | 13 | 14 (46.7) | 26,27,32,38-41,48,50,51 |
| Cefotaxime | IV | 100-200 | - | 5-14 | 80.8 (63.1 - 94.0) | 1 | 2 (6.6) | 24,25 |
| Ceftizoxime | IV | 100 | - | 2 | na |  | 1 (3.3) | 33 |
| Ceftazidime | IV | 150 | - | ≥2 | na |  | 1 (3.3) | 42 |
| 4th generation cephalosporins | | Cefepime | IV | 150 | - | 3 | na |  | 1 (3.3) | 42 |
| Aminoglycosides | | Isepamicin | IV | 15 | - | 4-14 | na |  | 2 (6.6) | 35,46 |
| Amikacin | IV | 15 | - | 2-14 | 93.5 (58.9- 100.0) | 1 | 5 (16.7) | 35,40,41,43,46 |
| Gentamicin | IV | 3-7.5 | - | 3-10 | 99.3 (97.6 - 100.0) | 6 | 5 (16.7) | 28,30,34,40,44 |
| Netilmicin | IV | 5-7.5 | - | 5-10 | (99.0 96.3- 100.0) | 2 | 2 (6.6) | 32,47 |
| Others | | Cotrimoxazole | po | 6-10/30-50\* | - | 7-14 | 88.4 (78.5 -95.8) | 3 | 5 (16.7) | 23,30,31,37,42 |
| Nitrofurantoin | po | 7 | - | 7-10 | na |  | 1 (3.3) | 41 |
| Ciprofloxacin | po | 20 | - | 7-10 | na |  | 1 (3.3) | 41 |
| Antibiotic not specified | | - | - |  | - | - | na |  | 1 (3.3) | 29 |
| Supplemental therapies | | Vitamin A | po | - | 1500/kg | 10 | na |  | 1 (3.3) | 43 |
| Vitamin E | po | - | 20-100 | 10-14 | na |  | 2 (6.6) | 43,50 |
| Vitamin C | po | 250mg/d | - | 14 | na |  | 1 (3.3) | 49 |
| Zinc | po | 1 | - | 14 | na |  | 1 (3.3) | 51 |
| N-acetyl-cysteine | po | 70 (or 600mg/d or 900mg/d based on age) | - | 5 | na |  | 1 (3.3) | 22 |
| Methylprednisolone | po | 1.6 | - | 3 | na |  | 1 (3.3) | 34 |

Abbreviations: po, per os; IV, intravenous; na, not available

\*presented as trimethoprim/sulfamethoxazole; \*\* of amoxicillin

† Cure rates are presented for the investigational drugs only if they represented the initial treatment given for those patients.